DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (AEDs), such as valproic acid, levetiracetam, topiramate, and lamotrigine.To date, perampanel is the only third-generation AED approved for generalized epilepsy. Neurologists consider many factors when choosing among the numerous first-, second-, and third-generation AEDs and must make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving journey of epilepsy patients with GOS provides important context about the complex, saturated, and heavily generic drug market that developers of new AEDs will enter, should they pursue an expanded labeling for GOS. For the first time, our 2019 Treatment Algorithms series offers this GOS segmentation, as well as a companion study on partial-onset seizures (POS).
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed epilepsy patients with GOS? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy GOS patients?
- How have Fycompa, Trokendi XR, and Qudexy XR been integrated into the treatment algorithm, and what is their source of business?
- What percentage of newly diagnosed epilepsy patients with GOS receive drug therapy within our tracking period, and how quickly do they receive it? What percentage of patients progress to later lines of therapy during our tracking period?
- What percentage of epilepsy patients with GOS are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with GOS?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Eisai, Supernus Pharmaceuticals, Upsher-Smith
Key drugs covered: Fycompa, Trokendi XR, Qudexy XR, clonazepam, phenytoin, levetiracetam, lamotrigine, valproate
Key analysis provided:
- Brand/therapy usage across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowchart.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Epilepsy - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Generalized Onset Seizures (US)
- Treatment Algorithms CDA-Epilepsy (Generalized Onset Seizures)-US-April 2019
Shefali Gulati, M.B.A.
Shefali Gulati, M.B.A., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She has authored several CNS/Ophthalmology reports, including U.S. Treatment Algorithms, Unmet need, Special topics. Previously, Ms. Gulati was a knowledge management associate with ZS Associates, where she worked on multiple client projects pertaining to real-world claims data analysis, opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds an M.B.A. in pharmaceutical management from the National Institute of Pharmaceutical Education and Research and a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research.